


PHARMACEUTICAL 2018

REVANCE

Revance Therapeutics Inc. Rank 143 of 349







PHARMACEUTICAL 2018

Revance Therapeutics Inc. Rank 143 of 349

The relative strengths and weaknesses of Revance Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Revance Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 337% points. The greatest weakness of Revance Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 98% points.

The company's Economic Capital Ratio, given in the ranking table, is -120%, being 157% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	285,211
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	20,902
Liabilities, Non-Current	0
Other Assets	1,238
Other Compr. Net Income	45
Other Expenses	3,384
Other Liabilities	5,952
Other Net Income	294
Property and Equipment	9,250
Research and Development	80,361
Revenues	262
Selling, General and Administrative Expense	37,398

Output Variable	Value in 1000 USD
Assets	295,699
Liabilities	26,854
Expenses	121,143
Stockholders Equity	268,845
Net Income	-120,587
Comprehensive Net Income	-120,564
Economic Capital Ratio	-120%

